Acrivon Therapeutics, Inc. (ACRV)

Acrivon Therapeutics' stock experienced a plunge following mixed cancer trial results in January 2026, but also saw a surge due to updated interim data for ACR-368 and expected early clinical data for ACR-2316. Insider buying activity was reported in January 2026. Acrivon announced a late-breaking oral presentation at the ESGO Annual International Congress for ACR-368 endometrial cancer data, and Piper Sandler raised its price target for ACRV. Short interest in ACRV increased, and the stock received mixed signals from moving averages in February 2026.

Acrivon Therapeutics, Inc. does not have products or services that are subject to demand seasonality. Its revenue and operational activities are primarily driven by research and development milestones, clinical trial progress, and potential future regulatory approvals and commercialization.

Acrivon Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology medicines, utilizing its AP3 platform to identify patients likely to respond to its drug candidates. Its pipeline includes ACR-368 (prexasertib), a CHK1 and CHK2 inhibitor in Phase 2 for solid tumors like endometrial and ovarian cancer, with FDA Fast Track designation for endometrial cancer and Breakthrough Device designation for its companion diagnostic. ACR-2316, a dual WEE1 and PKMYT1 inhibitor, is advancing in investigational new drug-enabling studies. ACR-6840, a CDK11 inhibitor, is planned for clinical trial requests in Q4 2026.

Acrivon Therapeutics, Inc. is headquartered in Redwood City, California, and Watertown, Massachusetts. The company collaborates with cancer centers and translational science groups across North America and Europe.

Acrivon Therapeutics generally holds a "Moderate Buy" or "Buy" consensus rating from analysts, with an average rating score of 2.50. The company's reputation has been positively influenced by promising clinical data presentations for its drug candidates and FDA designations. However, the stock experienced a notable plunge in January 2026 following "mixed cancer trial results." Insider buying by executives in early 2026 could be seen as a positive signal.

Acrivon Therapeutics, Inc. has 68 institutional owners and shareholders holding a total of 17,482,066 shares. Institutional ownership accounts for 76.05% of shares, while individuals hold 9.43%. Peter Blume-Jensen, the Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer, is a significant individual owner.